Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.09 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (pituicytes/fscs) | 0.10 |
| chemistry Open Targets | compounds already reach it: tezampanel anhydrous, selurampanel, topiramate +1 | 1.00 |
| trials ClinicalTrials.gov | 4 Parkinson's trials, 3 stopped | 0.40 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 2 pathways; mostly dopamine synapse | 1.00 |
No case: the score is under the bar. Receipt 2799
Sealed predictions
- GRIK3 in dopamine neurons, braak-0.67 (p 0.049) → +0.31 (p 0.414)receipt 2804
Swarm cases
receipt 2804: GRIK3 in dopamine neurons, braak
- power
- full sample -0.31 (p 0.218, n 18), 95% CI -0.68 to +0.19. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.29 (p 0.235, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.45 (p 0.059, n 18). could be the mix.
- skeptic
- leave-one-out range -0.46 to -0.22, sign flips 0; without severely affected donors -0.31 (p 0.218, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GRIK3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts